Advertisement

Resection Versus Chemotherapy for Metastatic Neuroendocrine Tumors of the Pancreas

  • Kathleen K. Christians
  • George Younan
  • Ben George
  • Susan Tsai
  • Douglas B. Evans
Chapter
Part of the Difficult Decisions in Surgery: An Evidence-Based Approach book series (DDSURGERY)

Abstract

Pancreatic neuroendocrine tumors (PNET) represent a broad spectrum of disease with behavior ranging from benign to highly malignant. Treatment strategies are quite variable and frequently lack consensus. This chapter focuses on the debate between surgery and chemotherapy for metastatic PNET. We summarize the evidence for both strategies including which treatment is appropriate in each clinical setting.

Keywords

Pancreatic neuroendocrine tumor Neuroendocrine carcinoma Ki67 mTOR inhibitors MGMT 

References

  1. 1.
    Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin Oncol. 2012;24:46–55.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Nilsson O, Van Cutsem E, Delle Fave G, et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology. 2006;84:212–5.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Ekeblad S, Skogseid B, Dunder K, et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798–803.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Hentic O, Couvelard A, Rebours V, et al. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer. 2011;18:51–9.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Oberg K. Pancreatic endocrine tumors. Semin Oncol. 2010;37:594–618.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Bettini R, Boninsegna L, Mantovani W, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008;19:903–8.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372–7.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98–119.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–76.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95:120–34.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469–92.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Sundin A, Vullierme MP, Kaltsas G, Plockinger U. ENETS guidelines for the standards of care in patients with neuroendocrine tumours: radiological examinations in patients with neuroendocrine tumours. Neuroendocrinology. 2009;90:167–83.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Kulke MH, Anthony LB, Bushnell DL, et al. NANETs treatment guidelines: well-differentated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39:735–52.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Frilling A, Li J, Malamutmann E, et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96:175–84.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg. 2007;245:273–81.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39:799–800.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Iwasa S, Morizane C, Okusaka T, et al. Cisplatin and etoposide as a first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010;40:313–8.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Kvols LK, Turaga KK, Strosberg J, Choi J. Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. J Natl Compr Canc Netw. 2009;7:765–72.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Norton JA, Warren RS, Kelly MG, et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057–65.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol. 2012;47:941–60.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Cauley CE, Pitt HA, Ziegler KM, Nakeeb A, Schmidt CM, Zyromski NJ, House MG, Lillemoe KD. Pancreatic enucleation: improved outcomes compared to resection. J Gastrointest Surg. 2012;16:1347–53.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Müller MW, Friess H, Kleeff J, Hinz U, Wente MN, Paramythiotis D, Berberat PO, Ceyhan GO, Büchler MW. Middle segmental pancreatic resection: an option to treat benign pancreatic body lesions. Ann Surg. 2006;244:909–18. discussion 918–920.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Cherif R, Gaujoux S, Couvelard A, Dokmak S, Vuillerme MP, Ruszniewski P, Belghiti J, Sauvanet A. Parenchymasparing resections for pancreatic neuroendocrine tumors. J Gastrointest Surg. 2012;16:2045–55.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Isla A, Arbuckle JD, Kekis PB, Lim A, Jackson JE, Todd JF, Lynn J. Laparoscopic management of insulinomas. Br J Surg. 2009;96:185–90.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    España-Gómez MN, Velázquez-Fernández D, Bezaury P, Sierra M, Pantoja JP, Herrera MF. Pancreatic insulinoma: a surgical experience. World J Surg. 2009;33:1966–70.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Daouadi M, Zureikat AH, Zenati MS, Choudry H, Tsung A, Bartlett DL, Hughes SJ, Lee KK, Moser AJ, Zeh HJ. Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann Surg. 2013;257:128–32.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, Hawkins WG. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg. 2014;259:197–203.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Tsutsumi K, Ohtsuka T, Mori Y, Fujino M, Yasui T, Aishima S, Takahata S, Nakamura M, Ito T, Tanaka M. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol. 2012;47:678–85.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Partelli S, Gaujoux S, Boninsegna L, Cherif R, Crippa S, Couvelard A, Scarpa A, Ruszniewski P, Sauvanet A, Falconi M. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NFPanNETs). JAMA Surg. 2013;148:932–9.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    D’Haese JG, Tosolini C, Ceyhan GO, et al. Update on surgical treatment of pancreatic neuroendocrine neoplasms. World J Gastroenterol. 2014;20(38):13893–8.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115:741–51.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, Jensen RT. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244:410–9.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, Fisher GA, Jensen RT. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011;146:724–32.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Pomianowska E, Gladhaug IP, Grzyb K, Røsok BI, Edwin B, Bergestuen DS, Mathisen O. Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems. Scand J Gastroenterol. 2010;45:971–9.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083–92.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg. 2006;244:845–51. discussion 852–853.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave G, Falconi M. Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review. Neuroendocrinology. 2011;93:223–9.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Bettini R, Mantovani W, Boninsegna L, et al. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis. 2009;41:49–55.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776–83. discussion 783–785.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Birnbaum DJ, Turrini O, Vigano L, et al. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study. Ann Surg Oncol. 2015;22:1000–7.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16:885–94.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Norton JA, Kivlen M, Li M, et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg. 2003;138:859–66.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Nguyen SQ, Angel LP, Divino CM, et al. Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol. 2007;96:397–403.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg. 2008;95:627–35.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multiinstitutional analysis. Ann Surg Oncol. 2010;17:3129–36.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Cusati D, Zhang L, Harmsen WS, Hu A, Farnell MB, Nagorney DM, Donohue JH, Que FG, Reid-Lombardo KM, Kendrick ML. Metastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver: surgical treatment and outcomes. J Am Coll Surg. 2012;215:117–24. discussion 124–125.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Tsuchikawa T, Kondo S, Hirano S, et al. Distal pancreatectomy and portal vein resection without vascular reconstruction for endocrine tumors with massive intraportal growth: report of a case. Hepatogastroenterology. 2011;58:1029–31.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Ochiai T, Masuda T, Nishizawa M, et al. Curative resection of a huge malignant pancreatic endocrine tumor by pancreaticoduodenectomy with portal and superior mesenteric vein resection and reconstruction using the right ovarian vein: report of a case. Surg Today. 2011;41:1260–5.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Okuno M, Sakaguchi S, Nagayama M, et al. Nonfunctioning islet cell carcinoma presenting bleeding gastric varices and splenomegaly. Jpn J Surg. 1984;14:244–7.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Yamaguchi T, Takahashi H, Kagawa R, et al. Nonfunctioning pancreatic endocrine tumor presenting with hemorrhage from isolated gastric varices. Am Surg. 2005;71:1027–30.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Hamilton NA, Liu TC, Cavatiao A, Mawad K, Chen L, Strasberg SS, Linehan DC, Cao D, Hawkins WG. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery. 2012;152:107–13.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R, Pederzoli P, Scarpa A, Falconi M. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67are predictors of recurrence after curative resections. Eur J Cancer. 2012;48:1608–15.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Pascher A, Klupp J, Neuhaus P. Endocrine tumours of the gastrointestinal tract. Transplantation in the management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19:637–48.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Harring TR, Nguyen NT, goss JA. Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol. 2011;2011:154541.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Gregoire E, Le Treut YP. Liver transplantation for primary or secondary endocrine tumors. Transpl Int. 2010;23:704–11.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH, Nashan B, Lang H, Klempnauer J, Manns MP, Boeker KH. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation. 2002;73:386–94.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Mazzaferro V, Pulvirenti A, coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007;47:460–6.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Steinmuller T, Kianmanesh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro) endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87:47–62.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Riccardi F, Rizzo M, Festino L, et al. Therapy innovation for the treatment of pancreatic neuroendocrine tumors. Expert Opin Ther Targets. 2012;16(Suppl 2):S91–102.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Eriksson B, Annibale B, Bajetta E, et al. ENETs consensus guidelines for the standards of care in neuroendocrine tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology. 2009;90:214–9.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Toumpanakis C, Meyer T, Caplin ME. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:131–44.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Maire F, Hammel P, Kianmanesh R, et al. Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after reseection of liver metastases from digestive endocrine tumors? Surgery. 2009;145:69–75.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Kos-Kudla B, O’Tool D, Falconi M, et al. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology. 2010;91:341–50.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol. 1999;17:615–30.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Sutliff VE, Doppman JL, Gibril F, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol. 1997;15:2420–31.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Kouvaraki MA, Ajani JA, Joff P, et al. Fluorouracil, doxorubicin and streptozocin in the treatem of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762–71.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268–75.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Maire F, Hammel P, Faivre S, et al. Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Neuroendocrinology. 2009;90:67–72.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Ekeblad S, sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13:2986–91.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Kulke MH, Hornick JL, Frauenhoffer C, et al. 06-methylguanin DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15:338–45.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Sideris L, Dube P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012;17:747–55.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19–31.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2010;16:2963–70.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Panzuto F, Di Francesco V, Iannicelli E, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. 2006;17:461–6.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind prospective randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. NEJM. 2014;371(3):224–33.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    The NCCN clinical practice guidelines in oncology for neuroendocrine tumors version 1.1.2012.Version1.2012.2012.online. go to www.nccn.org.
  82. 82.
    Miljkovic MD, Girotra M, Abraham RR, Erlich RB. Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig Dis Sci. 2012;57:9–18.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Oberg K. Somatostatin analog octreotide LAR in gastro-enteropancreatic tumors. Expert Rev Anticancer Ther. 2009;9:557–66.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Pavel M. Translation of molecular pathways into clinical trials of neuroendocrine tumors. Neuroendocrinology. 2013;97(1):99–112.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies. Curr Opin Oncol. 2010;22:381–6.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Yao JC. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007;21:163–72.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Vargas M, Gornals J, Ponseti JM, et al. Pancreatic endocrine tumors or apudomas. Rev Esp Enferm Dig. 2011;103:184–90.CrossRefGoogle Scholar
  88. 88.
    Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001(everolimus) and octreotide LAR in advanced low- to intermediate grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311–8.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic endocrine tumors. N Engl J Med. 2011;364:514–23.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Capurso G, Fazio N, Festa S, et al. Molecular target therapy for gastroenteropancreatic endocrine tumors: biological rationale and clinical perspectives. Crit Rev Oncol Hematol. 2009;72:110–24.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Raymond E, Hobday T, Castellano D, et al. Therapy innovations: tyrosine kinase inhibitors for te treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2011;30(Suppl 1):19–26.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Faivre S, Sablin MP, Dreyer C, Raymond E. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. Endocrinol Metab Clin N Am. 2010;39:811–26.CrossRefGoogle Scholar
  93. 93.
    Pavel ME, Wiedenmann B. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res. 2011;43:844–53.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Fjallskog ML, Lejonklou MH, Oberg KE, et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res. 2003;9:1469–73.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treat Options Oncol. 2011;12:136–48.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Raut CP, Kulke MH. Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist. 2011;16:286–95.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Van Vliet EI, Teunissen JJ, Kam BL, et al. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology. 2013;97(1):74–85.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Van Essen M, Krenning EP, Kam BL, et al. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009;5:382–93.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Kwekkeboom DJ, de Herder WW, Krenning EP. Somatostatin-receptor targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:173–85.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Rol of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139:742–53.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol. 2012;2012:819193.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006;24:3548–54.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Olsen IH, Langer SW, Jepsen I, et al. First line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide and vincristine: a single institution experience. Acta Oncol. 2012;51:97–100.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Massironi S, Conte D, Sciola V, et al. Plasma Chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol. 2010;105:2072–8.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Kathleen K. Christians
    • 1
  • George Younan
    • 1
  • Ben George
    • 1
  • Susan Tsai
    • 1
  • Douglas B. Evans
    • 1
  1. 1.Pancreatic Cancer Program, Medical College of Wisconsin; Department of Surgery (Division of Surgical Oncology)MilwaukeeUSA

Personalised recommendations